FDA Grants amyloid beta remover as the first Alzheimer’s drug instead of cannabinoids

On June 07, 2021 U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s. Alzheimer’s disease Alzheimer’s is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually, the ability to carry out simple tasks. While the specific causes of Alzheimer’s disease are not fully known, it is […]